• Source : Press Release
  • Date : 2021-12-20
  • Event type : Pre Clinical
  • Companies : GlaxoSmithKline Plc

Sosei Heptares to Receive Milestone from GSK as GPR35 Agonist Partnership Advances

Tokyo, Japan and Cambridge, UK, 20 December 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been recently notified by its partner GSK that a milestone has been reached under their 2020 Global Collaboration and License Agreement to discover and develop selective oral small molecule agonists of GPR35 as potential treatments for immune disorders of the digestive system.

The £5 million milestone payment (~US$6.7 million at current FX rates) will be recognized as revenue in the fourth quarter of the financial year ending December 31, 2021

GPR35 is an important orphan GPCR with genetic association to inflammatory bowel disease (IBD) and other gastrointestinal immune disorders, for which there remains significant unmet need for millions of sufferers worldwide.

About the agreement with GSK

Sosei Heptares and GSK entered into a Global Collaboration and License Agreement in December 2020, under which GSK licensed global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design (SBDD) platform and supported by strong translational science investment in gastrointestinal biology. Sosei Heptares and GSK are jointly conducting the research and early preclinical development phases, and GSK will lead clinical development, manufacturing and commercialization. Further details of the agreement can be found by clicking here.


About Sosei Heptares 

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. 

We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer and Takeda. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. 

For more information, please visit 
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco


Sosei Heptares – Media and Investor Relations 
Hironoshin Nomura, SVP Investor Relations and Corporate Strategy 
81 (0)3 6679 2178 | [email protected]

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures 
81 (0)3 5210 3399 | [email protected] 

Citigate Dewe Rogerson (for Japanese Media) 
Yas Fukuda 
81 (0)3 4360 9234, [email protected] 

MEDiSTRAVA Consulting (for International Media) 
Mark Swallow, David Dible, Eleanor Perkin 
44 (0)20 7638 9571, [email protected]

Forward-looking statements 

This release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwi